Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience

References

• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359(9311):1011-8
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996;39(2):235-50
   PubMed Web of Science ®Google Scholar
• Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21(8):1624-36
   PubMed Web of Science ®Google Scholar
• Gliadel® Wafer [prescribing information]. MGI PHARMA, Bloomington, MN, USA, 2006
   Google Scholar
• Gliadel® Wafer [summary of product characteristics]. West Sussex, UK, 2006
   Google Scholar
• Temodar® [prescribing information]. Schering Corp, Kenilworth, NJ, 2005
   Google Scholar
• Sampath P, Brem H. Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 1998;5(2):130-7
   PubMedGoogle Scholar
• Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002;41(6):403-19
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345(8956):1008-12
   Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 2003;5(2):79-88
   PubMed Web of Science ®Google Scholar
• Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006;148(3):269-75
   PubMed Web of Science ®Google Scholar
• Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58(4):672-84
   PubMed Web of Science ®Google Scholar
• Giese A, Kucinski T, Knopp U, et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neuro-oncol 2004;66(3):351-60
   PubMed Web of Science ®Google Scholar
• MGI PHARMA. Gliadel Wafer: Heath Care Professionals. Available at: http://www.gliadel.com/hcp/default.aspx [Last accessed 21 February 2008]
   Google Scholar
• Rabadan AT, Hernandez D, Eleta M, et al. Factors related to surgical complications and their impact on the functional status in 236 open surgeries for malignant tumors in a Latino-American hospital. Surg Neurol 2007;68(4):412-20
   PubMed Web of Science ®Google Scholar
• McGovern PC, Lautenbach E, Brennan PJ, et al. Risk factors for postcraniotomy surgical site infection after 1,3-bis(2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis 2003;36(6):759-65
   PubMed Web of Science ®Google Scholar
• Chopko BW, Park N, Golden GA, et al. PROLONG (Prospective Look at Outcomes Nationally with GLIADEL): interim report on the malignant glioma experience. Abstract presented at the Annual Meeting of the American Association of Neurological Surgeons, 2004
   Google Scholar
• Asher AL. Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma. Abstract presented at the Annual Meeting of the American Association of Neurological Surgeons, Washington, DC, 2007
   Google Scholar
• Carmona DMM, Cantamessa CF, García-Salazar MM, et al. Nuevas perspectivas en el tratamiento paliativo del glioblastoma multiforme y astrocitoma anaplásico recidivado con implantes de carmustina. Oncología 2005;28(5):249-57
   Google Scholar
• Dal Pan G, Butler L, Schactman M. Preliminary analysis of the GLIADEL treatment protocol. Abstract presented at the ASCO Annual Meeting, Atlanta, GA, 1997
   Google Scholar
• Darakchiev BJ, Albright RE, Breneman JC, et al. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 2008;108(2):236-42
   PubMed Web of Science ®Google Scholar
• Eiras-Ajuria J, Rivero-Celada D, Alberdi-Viñas J, et al. A novel approach for treating deep-seated high-grade gliomas (HGG): resection and sealed-cavity implantation of carmustine (BCNU) wafer with minimally invasive surgery (MIS). Poster and abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Chicago, IL, 2006
   Google Scholar
• González Vidal D. The safety of Gliadel® implants during the indication period in recurrent surgery in the treatment of Glioblastoma Multiforme (April 2003 – April 2005) [abstract]. Neurocirugía 2006;17(2 Suppl 1):77-8
   Google Scholar
• Gururangan S, Cokgor L, Rich JN, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology 2001;3(4):246-50
   PubMed Web of Science ®Google Scholar
• Heery CR, Desjardins A, Quinn JA, et al. Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma [abstract]. J Clin Oncol 2006;24(18S):11504
   Google Scholar
• Kleinberg LR, Weingart J, Burger P, et al. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 2004;22(1):1-9
   PubMed Web of Science ®Google Scholar
• LaRocca R, Glisson S, Hargis J, et al. High-grade glioma treated with surgery; carmustine wafer; postoperative radiation; and procarbazine, lomustine, and vincristine chemotherapy. Neurosurg Quart 2005;15(3):167-71
   Web of Science ®Google Scholar
• Licastro GM, Tonnarelli GP. Use of Gliadel wafers in glioblastom multiforma: our experience. Rivista Medica 2007;13(4):111-8
   Google Scholar
• Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neuro-oncol 2008;88(3):353-7
   PubMed Web of Science ®Google Scholar
• Quinn JA, Vredenburgh JJ, Rich JN, et al. Phase II trial of Gliadel plus O6-benzylguanic (O6-BG) for patients with recurrent glioblastoma multiforme [abstract]. J Clin Oncol 2007;25(18S):2036
   Google Scholar
• Sampath P, Sungarian A, Alderson L., et al. BCNU-impregnated wafers (Gliadel) plus irinotecan (Camptosar) in combination treatment for patients with recurrent glioblastoma multiforme. Poster and abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Boston, MA, 2005
   Google Scholar
• Sampath P, Weaver CE, Alderson L, et al. Consecutive use of brachytherapy (Gliasite) and intratumoral chemotherapy (Gliadel) for recurrent glioblastoma: a Phase I/II study with independent clinical review. Poster and abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Boston, MA, 2005
   Google Scholar
• Tait MJ, Critchley GR. Experience of revision craniotomy for debulking of high grade gliomas in 27 patients in a single UK centre, with and without insertion of carmustine wafers, Meeting of the Society of British Neurosurgeons, Preston, UK, 2006
   Google Scholar
• Tozer K, Silbergeld DL, Rostomily RC, et al. Concomitant use of Gliadel and permanent low-activity I-125 seed implants for recurrent malignant glioma. abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Denver, CO, 2003
   Google Scholar
• Uff CEG, Bradford R. Use of Gliadel (BCNU) Wafers in high grade glioma. Abstract presented at the meeting of the Society of British Neurosurgeons, Plymouth, UK, 2005
   Google Scholar
• Weingart J, Grossman SA, Carson KA, et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2007;25(4):399-404
   PubMed Web of Science ®Google Scholar
• Zamorano L, Li Q, Levin K., et al. Brachytherapy with I-125 permanent implant combined with sequential Gliadel in the treatment of patients with GBM. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Boston, MA, 2005
   Google Scholar
• Blandini G, Barone F, Ventara F. Adjuvant treatment of high-grade gliomas with Gliadel: preliminary experience. Rivista Medica 2007;13(4):131-3
   Google Scholar
• Kalra R, Zahner M, Nicoletti LK, et al. Retrospective analysis of the clinical usage of the chemotherapy agent Gliadel wafer in patients with malignant gliomas. Neuro-Oncology 2006;4:444
   Google Scholar
• Subach BR, Witham TF, Kondziolka D, et al. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 1999;45(1):17-22
   PubMed Web of Science ®Google Scholar
• LaRocca RV, Hodes J, Villanueva WG, et al. A Phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion [abstract]. Abstract presented at the Annual Meeting of the Society of Neuro-oncology, Orlando, FL, 2006
   Google Scholar
• Zeltzer PM, Black KL, Adamson P, et al. A Phase 1/2 feasibility trial of surgery, Gliadel® Wafer and neoadjuvant continuous infusion vincristine (CIV) for patients with recurrent or progressive anaplastic astrocytoma or glioblastoma multiforme [abstract]. Neuro-Oncology 2002;4(4):241-395
   Google Scholar
• Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9
   PubMed Web of Science ®Google Scholar
• Afra D, Norman D, Levin VA. Cysts in malignant gliomas. Identification by computerized tomography. J Neurosurg 1980;53(6):821-5
   Google Scholar
• Bohinski RJ, Kokkino AK, Warnick RE, et al. Glioma resection in a shared-resource magnetic resonance operating room after optimal image-guided frameless stereotactic resection. Neurosurgery 2001;48(4):731-42
   PubMed Web of Science ®Google Scholar
• Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 1997;33(10):1592-6
   PubMed Web of Science ®Google Scholar
• Brell M, Ibanez J, Caral L, et al. Factors influencing surgical complications of intra-axial brain tumours. Acta Neurochir (Wien) 2000;142(7):739-50
   PubMed Web of Science ®Google Scholar
• Cabantog AM, Bernstein M. Complications of first craniotomy for intra-axial brain tumour. Can J Neurol Sci 1994;21(3):213-8
   PubMed Web of Science ®Google Scholar
• Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg 2003;98(6):1175-81
   PubMed Web of Science ®Google Scholar
• Constantini S, Cotev S, Rappaport ZH, et al. Intracranial pressure monitoring after elective intracranial surgery. A retrospective study of 514 consecutive patients. J Neurosurg 1988;69(4):540-4
   Google Scholar
• Dhami MS, Bona RD, Calogero JA, et al. Venous thromboembolism and high grade gliomas. Thromb Haemostasis 1993;70(3):393-6
   PubMed Web of Science ®Google Scholar
• Fadul C, Wood J, Thaler H, et al. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 1988;38(9):1374-9
   PubMed Web of Science ®Google Scholar
• Hase U, Reulen HJ, Schubert R, et al. The course of intracranial pressure and volume–pressure relationships following extirpation of meningiomas and astrocytomas. Acta Neurochir (Wien) 1978;44(3-4):161-71
   PubMed Web of Science ®Google Scholar
• Rasmussen M, Bundgaard H, Cold GE. Craniotomy for supratentorial brain tumors: risk factors for brain swelling after opening the dura mater. J Neurosurg 2004;101(4):621-6
   PubMed Web of Science ®Google Scholar
• Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983;13(3):334-6
   PubMed Web of Science ®Google Scholar
• Sawaya R, Zuccarello M, Elkalliny M, et al. Postoperative venous thromboembolism and brain tumors: part I. Clinical profile. J Neuro-oncol 1992;14(2):119-25
   PubMed Web of Science ®Google Scholar
• Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998;42(5):1044-55
   PubMed Web of Science ®Google Scholar
• Tandon PN, Mahapatra AK, Khosla A. Epileptic seizures in supratentorial gliomas. Neurol India 2001;49(1):55-9
   PubMed Web of Science ®Google Scholar
• Taylor MD, Bernstein M. Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors: a prospective trial of 200 cases. J Neurosurg 1999;90(1):35-41
   PubMed Web of Science ®Google Scholar
• Tenney JH, Vlahov D, Salcman M, et al. Wide variation in risk of wound infection following clean neurosurgery. Implications for perioperative antibiotic prophylaxis. J Neurosurg 1985;62(2):243-7
   Google Scholar
• Volc D, Jellinger K, Flament H, et al. Cerebral space-occupying cysts following radiation and chemotherapy of malignant gliomas. Acta Neurochir (Wien) 1981;57(3-4):177-93
   PubMed Web of Science ®Google Scholar
• Oertel J, von Buttlar E, Schroeder HW, et al. Prognosis of gliomas in the 1970s and today. Neurosurg Focus 2005;18(4):e12
   Google Scholar
• Tamargo RJ, Epstein JI, Reinhard CS, et al. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 1989;23(2):253-66
   PubMed Web of Science ®Google Scholar
• Semrad TJ, O’Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007;106(4):601-8
   PubMed Web of Science ®Google Scholar
• Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89(4):640-6
   PubMedGoogle Scholar
• Eiras-Ajuria J, Rivero-Celada D, Alberdi-Viñas J, et al. Minimally invasive craniotomy to apply carmustine wafers in a tight cavity to improve safety and efficacy in malignant gliomas. Abstract presented at the Congress of the European Association of Neurooncology, Vienna, Austria, 2006
   Google Scholar
• Vorster SJ, H. BG. A proposed preoperative grading scheme to assess risk for surgical resection of primary and secondary intraaxial supratentorial brain tumors. Neurosurg Focus 1998;4(6):e2
   Google Scholar
• Kole M, Rock J. Malignant Glioma Surgery: Complication Avoidance. Neurosurg Quart 2002;12(3):251-8
   Web of Science ®Google Scholar
• Prestwich RJ, Sivapalasunrtharam A, Johnston C, et al. Survival in high-grade glioma: a study of survival in patients unfit for or declining radiotherapy. Clin Oncol (R Coll Radiol) 2005;17(3):133-7
   PubMed Web of Science ®Google Scholar
• Toms SA, Ferson DZ, Sawaya R. Basic surgical techniques in the resection of malignant gliomas. J Neuro-oncol 1999;42(3):215-26
   PubMed Web of Science ®Google Scholar
• Lawson HC, Sampath P, Bohan E, et al. Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neuro-oncol 2007;83(1):61-70
   PubMed Web of Science ®Google Scholar
• Final appraisal determination – carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. National Institute for Health and Clinical Excellence, 2007. Available at: http://www.nice.org.uk/nicemedia/pdf/Glioma_carmustine_FAD.pdf [Last accessed 6 May 2008]
   Google Scholar
• Clinical Practice Guidelines in Oncology. Central Nervous System Cancers, edition v.1.2008. National Comprehensive Cancer Network, 2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf [Last accessed 5 May 2008]
   Google Scholar
• Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre Phase III trial. Lancet Oncol 2006;7(5):392-401
   PubMed Web of Science ®Google Scholar
• Golden GA, Meldorf M, , PROLONG Study Group. Number of wafers used in a cohort of 322 patients implanted with Gliadel Wafer [abstract]. Neuro-Oncology 2004;6(4):307-400
   Google Scholar
• Krzeminski JP, Meldorf MG, Agarwal S. Repeated implantation of the Gliadel Wafer to treat malignant gliomas. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Denver, CO, 2003
   Google Scholar
• Ewend MG. Polymer-based local therapy. 2007. Available at: http://www.gliomaed.com/topic_detail.asp?id=10 [Last accessed 22 May 2008]
   Google Scholar
• Thompson RC, Motwani SB, Riedinger MS, et al. Clinical variables associated with development of communicating hydrocephalus following resection of astrocytoma. Abstract presented at the Annual Meeting of the American Association of Neurological Surgeons, Chicago, IL, 2002
   Google Scholar
• Chopko B, Golden GA, Meldorf M. PROLONG® (Prospective Look at Outcomes Nationally with GLIADEL®): report on patient care practices with GLIADEL® implantation in brain cancer. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, San Francisco, CA, 2004
   Google Scholar
• Korinek AM, Golmard JL, Elcheick A, et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br J Neurosurg 2005;19(2):155-62
   PubMed Web of Science ®Google Scholar
• Fung LK, Shin M, Tyler B, et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res 1996;13(5):671-82
   PubMed Web of Science ®Google Scholar
• Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000;53(5):458-64
   PubMed Web of Science ®Google Scholar
• MGI PHARMA. How to Use GLIADEL® Wafer. 2007. Available at: http://www.gliadel.com/hcp/about/how.aspx [Last accessed 6 May 2008]
   Google Scholar
• Bertin ML, Mani A, Barnett G, et al. Risk factors for surgical site infection after 1,3-bis(2-chlorethyl)-1-nitrosurea (BCNU) Gliadel Wafer implatation for glioblastoma [abstrac]. Infect Control Hosp Epidemiol 2000;21(2):144
   Google Scholar
• Jones NS, Becker DG. Advances in the management of CSF leaks. BMJ 2001;322(7279):122-3
   PubMed Web of Science ®Google Scholar
• Gottfried ON, Deogaonkar M, Way DL, et al. Postoperative cerebral edema after intracavitary implantation of Gliadel(R) wafers for treatment of malignant gliomas [abstract]. J Invest Med 2000;48(1):79
   Google Scholar
• Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: two case studies. Neuro-Oncology 2005;7(1):84-9
   PubMed Web of Science ®Google Scholar
• Highsmith JM, Broaddus WC. Reduction of Complications with Carmustine Wafers. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Boston, MA, 2005
   Google Scholar
• Brem H, Mahaley MS, Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74(3):441-6
   PubMed Web of Science ®Google Scholar
• Management of peritumoral edema. European Association of Neurooncology, 2003. Available at: http://www.eano.eu/documents/guidelines/Management_of_Peritumoural_Edema.pdf [Last accessed 6 May 2008]
   Google Scholar
• Raslan A, Bhardwaj A. Medical management of cerebral edema. Neurosurg Focus 2007;22:E12
   Google Scholar
• Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005;293(5):557-64
   PubMed Web of Science ®Google Scholar
• Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004;79(12):1489-94
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54(10):1886-93
   PubMed Web of Science ®Google Scholar
• van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007;6(5):421-30
   PubMed Web of Science ®Google Scholar
• Hughes MA, Parisi M, Grossman S, et al. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005;62(5):1423-6
   PubMed Web of Science ®Google Scholar
• Barker F. Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis. Neurosurgery 1994;35:484-92
   PubMed Web of Science ®Google Scholar
• Barker FG 2nd. Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis. Neurosurgery 2007;60(5):887-94; discussion 94
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S
   PubMed Web of Science ®Google Scholar
• Engelhard HH, Maher de Leon ME, Rozental JM. Tumor bed cyst formation after BCNU wafer implantation. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Seattle, WA, 1998
   Google Scholar
• McGirt MJ, Villavicencio AT, Bulsara KR, et al. Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. J Neurosurg 2002;96(5):941-5
   PubMed Web of Science ®Google Scholar
• Sampath R, Brem S, Wotoczek-Obadia M, et al. MR findings to differentiate physiological responses from neoplastic progression or brain abscess in patients with brain tumors treated with implantable chemotherapeutic-wafers. Poster and abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Chicago, IL 2006
   Google Scholar
• de Wit MC, de Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63(3):535-7
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neuro-oncol 2007;82(1):81-3
   PubMed Web of Science ®Google Scholar
• Hammoud DA, Belden CJ, Ho AC, et al. The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging. Am J Roentgenol 2003;180(5):1469-75
   PubMed Web of Science ®Google Scholar
• Khan AK, Tobias M, Sungarian A, et al. Post-operative pneumocephalus following carmustine polymer placement mimicking intracranial infection: report of four cases. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, San Antonio, TX, 2000
   Google Scholar
• Prager JM, Grenier Y, Cozzens JW, et al. Serial CT and MR imaging of carmustine wafers. Am J Neuroradiol 2000;21(1):119-23
   PubMed Web of Science ®Google Scholar
• Deogaonkar M, Way D, Gottfried O, et al. Persistent intracranial air and increased postoperative vasogenic edema after intracavitatory implantation of Gliadel wafers for malignant gliomas. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Boston, MA, 1999
   Google Scholar
• Smith KA, Ashby L, Gonzolas F. Gross total resection (GTR) with Gliadel® Wafer implantation followed by post-operative gamma knifetm radiosurgery and adjuvant fractionated radiotherapy for newly diagnosed GBM: Phase I/II study of safety and efficacy in 30 consecutive patients. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Chicago, IL, 2006
   Google Scholar
• Limentani SA, Asher A, Heafner M, et al. A Phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neuro-oncol 2005;72(3):241-4
   PubMed Web of Science ®Google Scholar
• Lawson DH, Phuphanich S, McKenzie E, et al.Phase I analysis of systemic interferon alpha utilized with gliadel in adults with recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I Vol 24, No 18S (June 20 Supplement), 2006: 11508
   Google Scholar
• Spiegel BM, Esrailian E, Laine L, et al. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 2007;21(9):775-87
   PubMed Web of Science ®Google Scholar
• Ashby LS, Ryken TC. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus 2006;20(4):E3
   PubMedGoogle Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. New Engl J Med 2008;359(5):492-507
   PubMed Web of Science ®Google Scholar
• Lesniak MS, Brem H. Targeted therapy for brain tumours. Nat Rev Drug Discov 2004;3(6):499-508
   PubMed Web of Science ®Google Scholar